Acute Administration of 10 mg Methylphenidate on Cognitive Performance and Visual Scanning in Healthy Adults:
Blair Aitken1, Luke A Downey1,2, Serah Rose1
1Centre for Mental Health and Brain Sciences, Swinburne University of Technology, Hawthorn, Australia.
Objective:
To examine the effect of a low dose (10 mg) of methylphenidate on cognitive performance, visuospatial working memory (VSWM) and gaze behaviour capabilities in healthy adults.
Methods:
This randomised, double-blind, placebo-controlled and crossover study examined the effects of 10 mg methylphenidate on cognitive performance, VSWM and gaze behaviour. Fixation duration and rate, gaze transition entropy, and stationary gaze entropy were used to quantify visual scanning efficiency in 25 healthy adults (36% female, mean ± SD age = 33.5 ± 7.8 years, BMI = 24.1 ± 2.9 kg/m2). Attention, memory, and reaction time were assessed using the E-CogPro test battery.
Results:
Methylphenidate significantly enhanced performance in numeric working memory tasks, reflected by reduced errors and increased accuracy relative to placebo. No significant changes were observed in other cognitive or visual scanning metrics.
Conclusions:
A low dose of methylphenidate improves limited domains of psychomotor speed and accuracy but does not affect visual scanning efficiency. This suggests limited usefulness as a general pro-cognitive aid and raises the possibility of a lower threshold of effect for measurable psychostimulant-induced changes to visual scanning behaviour. Further research is needed to explore these potential dose-response relationships and effects across diverse populations.
Trial Registration:
ACTRN12620000499987.
More Related Videos
06:58Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
10:02Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
Published on: March 12, 2020
Related Concept Videos
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
